| |
Tuesday, May 20, 2025 | 11am ET / 8am PT This webinar will feature industry experts discussing the power of combining biomedical data analysis with matched tissue and molecular samples. Register today. 
|
|
Today’s Big NewsMay 15, 2025 |
|
Wednesday, May 28, 2025 | 11am ET / 8am PT Join us to learn more about Integrated Drug Discovery (IDD), and explore the complexity of integrating multidisciplinary functions, including chemistry, biology, pharmacology, project and data management, advanced technologies, and regulatory compliance. Learn how to navigate the drug discovery journey and overcome common challenges. Register now. 
|
|
| By Darren Incorvaia An infant named KJ has made history as the first patient to be treated with an in vivo CRISPR gene editing therapy designed specifically for him. |
|
|
|
By Fraiser Kansteiner Citing tariff threats, Merck KGaA has lowered its sales guidance for its life science arm, which offers various R&D and CDMO services, plus key materials for partners. |
By Conor Hale WASHINGTON, D.C.—Speaking at the annual Food & Drug Law Institute conference in Washington, D.C., Martin Makary, M.D., said implementing AI is one of the agency’s top priorities. |
By James Waldron Pathos AI has secured $365 million in series D funds as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. |
|
Thursday, May 29, 2025 | 11am ET / 8am PT While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. It is more important than ever to implement strategies and solutions for maximizing efficiencies throughout the drug development process. Join us to learn more. 
|
|
By Andrea Park Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for certain consumers, many are still turned off by the meds’ sticker shock. |
By Nick Paul Taylor Biohaven is giving investors whiplash. Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA has delayed a decision on its rare disease candidate troriluzole and plans to hold an advisory committee to discuss the application. |
By Zoey Becker Merck's cancer superstar Keytruda has not yet been able to add an ovarian cancer-specific nod to its impressive lineup of approved indications. Now, the drug has shown benefits for patients with platinum-resistant recurrent ovarian cancer. |
By James Waldron Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in order to keep resources flowing toward its leukemia candidate. |
By Zoey Becker GSK tapped "Buffy the Vampire Slayer" actresses Alyson Hannigan and Sarah Michelle Gellar to promote the upcoming company-sponsored Lifetime Original Movie "Pretty Hurts," in which a pageant girl and her mom are hit with the reality of meningitis B. |
By Fraiser Kansteiner The FDA granted an accelerated approval to AbbVie’s c-Met-directed ADC Emrelis as a new treatment option for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer who’ve previously received systemic therapy. The green light equips AbbVie with a second commercial ADC after Elahere, which it acquired in its $10.1 billion buyout of ImmunoGen. |
By Conor Hale The medtech’s 10th annual Future Health Index report polled nearly 2,000 professionals and more than 16,000 patients across 16 countries. |
By Nick Paul Taylor GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by gene therapies such as Sarepta Therapeutics’ Elevidys and Novartis’ Zolgensma. |
By Kevin Dunleavy Six years after Merck bought out Peloton Therapeutics, the New Jersey drugmaker is not remaining stationary with the crown jewel of the deal. The FDA has approved a third indication for Welireg, signing off on the hypoxia-inducible factor-2 alpha inhibitor to treat patients with rare pheochromocytoma or paraganglioma tumors in the endocrine system. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Angela Hwang reflects on her leap from nearly 30 years at Pfizer to leading a biotech startup—and the career lessons that continue to guide her leadership and commitment to developing diverse talent. |
|
|---|
|
|
Whitepaper Don’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
Whitepaper Learn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
Whitepaper We interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
.png){kind=spacer}
